NCT02062294已完成不适用
Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 3
- 主要终点
- Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis
研究概览
简要总结
This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in preventing Cytomegalovirus (CMV) disease in D+/R- liver transplant recipients. Data from eligible patients will be collected for the 6 months following transplantation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Liver transplant recipients, >/= 16 years of age
- •Transplantation between January 2004 and June 2009
- •CMV seronegative recipient (R-) who received a liver transplant from a seropositive donor (D+)
- •Valganciclovir therapy for at least 70 days beginning within 10 days post transplantation
- •Assessment of CMV disease status within the first 6 months post transplantation
排除标准
- 未提供
结局指标
主要结局
Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis
时间窗: 6 months
Participants with clinical manifestation of CMV disease within 6 months after liver transplantation under Valcyte prophylaxis were evaluated.
次要结局
- Number of Participants With Any Serious Adverse Events (SAEs) or Adverse Events (AEs)(6 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected PatientsCytomegalovirus InfectionsHIV InfectionsNCT00001038National Institute of Allergy and Infectious Diseases (NIAID)1,200
已完成
3 期
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell TransplantationCancerNCT00045292Fred Hutchinson Cancer Center
已完成
3 期
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell TransplantationInfectionNCT00016068Fred Hutchinson Cancer Center184
已完成
1 期
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of AgeCytomegalovirus Infections, Heart TransplantationNCT01165580Hoffmann-La Roche17
终止
3 期
MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by CytomegalovirusCytomegalovirus InfectionsInflammatory Bowel DiseasesNCT00237653University Hospital, Grenoble40